Drug intelligence / Profile preview

Buqi Jiedu Huayu granule

Development stage: Preclinical
Lead developer: Shanghai Municipal Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Buqi Jiedu Huayu granule is a Traditional Chinese Medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is primarily investigated for the treatment of primary thrombocytosis (also known as essential thrombocythemia). The formulation is based on TCM principles of tonifying Qi (Buqi), detoxifying (Jiedu), and resolving blood stasis (Huayu). In clinical research, it is evaluated as an adjunctive therapy to hydroxyurea, aiming to improve therapeutic efficacy and reduce the symptom burden in patients with myeloproliferative disorders.

Brand names: Buxu Jiedu Huayu Decoction
Other names: Buxu Jiedu Huayu granuleBuxu Jiedu Huayu DecoctionBuqi Jiedu Huayu Decoction

Beyond the preview

Go deeper on Buqi Jiedu Huayu granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buqi Jiedu Huayu granule.

Explore the full profile